David J Brillon   Professor Emeritus of Clinical Medicine

  • +1 646 962 8690

Effects of Glycemic Control on Diabetes Complications

Dr Brillon is the Principal Investigator at the Weill Cornell site for two multi-center trials evaluating the development of complications in both type 1 and type 2 diabetes mellitus.The Epidemiology of Diabetes Intervention and Complications Trial (EDIC) is a continuation of the Diabetes Control and Complications Trial (DCCT). The DCCT evaluated the effects of intensive versus conventional glucose therapy in over 1300 persons with type 1 diabetes. The DCCT was one of the first trials demonstrating that intensive glucose control can significantly reduce the development and progression of microvascular complications in individuals with type 1 diabetes mellitus compared to conventional glucose control. EDIC is an observational 10 year follow-up study of the DCCT cohort. EDIC has so far found that the effects of the 6.5 years of intensive control in reducing the rate of progression of microvasular disease persist for up to 8 years after cessation of intensive therapy. EDIC has also demonstrated reductions in cardiovascular disease outcomes with the use of intensive therapy. The study cohort will be followed for an additional 10 year period.The Action to Control Cardiovascular Risk in Diabetes (ACCORD ) trial is a multi-center study of the effects of intensive versus conventional glucose, blood pressure and lipid treatment on cardiovascular disease in 10,000 individuals with type 2 diabetes mellitus. Dr. Brillon is also involved with Dr. Francesco Rubino of the Metabolic Surgery Division on several trials evaluating the effects of bariatric surgery on diabetes mellitus.


Sort by

Selected publications



Primary Email

  • djbrillo@med.cornell.edu


Primary Affiliation

  • Weill Cornell Medical College, Cornell University